Factors Associated With Success of NIPPV in ALS Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05581771 |
Recruitment Status :
Active, not recruiting
First Posted : October 17, 2022
Last Update Posted : November 1, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
ALS |
Study Type : | Observational |
Actual Enrollment : | 51 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Factors Associated With Success of Non-invasive Positive Pressure Ventilation in Patients With Amyotrophic Lateral Sclerosis: A Retrospective Cohort Study |
Actual Study Start Date : | October 18, 2022 |
Actual Primary Completion Date : | October 27, 2022 |
Estimated Study Completion Date : | September 22, 2023 |

- Success of NIPPV [ Time Frame: through intervention completion, with an average of 10 days ]The success of NIPPV application was defined empirically as use of ≥ 2 hours per day and the failure as use of < 2 hours for a day or conversion to invasive positive pressure ventilation via tracheostomy or refuse to apply NIPPV during hospitalization.
- Lenght of stay [ Time Frame: through intervention completion, with an average of 10 days ]The length of stay (LOS) was defined as the interval between admission and hospital discharge, and calculated as the number of midnights between admission and discharge from the hospital.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients fulfilling the El Escorial World Federation criteria for probable, or definite ALS
- Aged ≥ 19 years
- Patients who performed blood gas analysis including venous blood gas and arterial blood gas before NIPPV application.
Exclusion Criteria:
- Patients who had experience in applying the NIPPV or currently using NIPPV
- Patients who applied in outpatient settings
- Patients who did not perform blood gas analysis before NIPPV application
- Patietns who had a history of asthma or COPD,
- Patients who didn't have any record of NIPPV application time

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05581771
Korea, Republic of | |
Seoul National University Bundang Hospital | |
Seongnam-si, Korea, Republic of, 13620 |
Principal Investigator: | Jaewon Beom, PhD | Department of Rehabilitation Medicine, Seoul National University Bundang Hospital |
Responsible Party: | Jaewon Beom, Clinical Associate Professor, Seoul National University Bundang Hospital |
ClinicalTrials.gov Identifier: | NCT05581771 |
Other Study ID Numbers: |
B-2210-786-107 |
First Posted: | October 17, 2022 Key Record Dates |
Last Update Posted: | November 1, 2022 |
Last Verified: | October 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Noninvasive positive pressure ventilation Amyotrophic lateral sclerosis Adherence |
Amyotrophic Lateral Sclerosis Motor Neuron Disease Neurodegenerative Diseases Nervous System Diseases Neuromuscular Diseases |
Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases |